Cell Therapeutics, Inc. (CTIC) announced that Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of the company's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma, or NHL, patients.
The company revealed 70% CR/CRu rate in a phase II trial in patients treated with pixantrone plus FPD-R regimen in relapsed/refractory indolent NHL. The company also announced 47% CR/CRu rate in a phase II trial in patients treated with CPOP regimen for patients that failed CHOP regimen with relapsed/refractory aggressive NHL. Cell Therapeutics further disclosed 35% CR rate in a phase III trial in patients treated with pixantrone plus rituximab in relapsed/refractory indolent NHL.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.